San Diego-dependent Viking Therapeutics marked by itself as a significant competitor inside the weight loss drug market in February after revealing promising info from the mid-phase trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when presented as being a weekly injection As well as in March the